Document Detail

Etanercept: effective in the management of hidradenitis suppurativa.
MedLine Citation:
PMID:  16536817     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic suppurative condition which is poorly responsive to treatment and is characterized by significant morbidity. Successful treatment of HS in patients treated with infliximab for concomitant Crohn's disease has been reported. More recent reports of positive responses to infliximab [an antitumour necrosis factor (TNF)-alpha agent] in patients who have HS but not Crohn's disease are encouraging. OBJECTIVES: TNF-alpha is implicated in many inflammatory disorders and we wished to determine the efficacy of subcutaneous etanercept, a competitive inhibitor of TNF-alpha in the control of HS symptoms. METHODS: We commenced six patients with severe, recalcitrant HS on etanercept (25 mg subcutaneously twice weekly in all cases). All patients had a normal chest X-ray and negative purified protein derivative test prior to treatment and were closely monitored throughout the treatment period for signs of infection. Patients self-assessed their disease activity and completed Dermatology Life Quality Index (DLQI) questionnaires immediately before the introduction of therapy and 24 weeks later in the case of four patients, and 12 weeks later in the case of two others. All patients were asked to estimate the time lapse between commencement of treatment and initial response. RESULTS: Treatment was well tolerated by all patients with no reported adverse reactions. A marked reduction in self-reported disease activity (mean reduction of 61% at 24 weeks), in DLQI scores (mean reduction of 64% at 24 weeks) and in relapse rates occurred. All patients rated etanercept as their most effective treatment to date. CONCLUSIONS: Our results show the effectiveness of etanercept in this group of patients with particularly challenging disease. Etanercept, unlike infliximab, may be administered subcutaneously, rendering costly day-case admissions unnecessary.
C Cusack; C Buckley
Related Documents :
19685057 - The relation between osteoporosis and vitamin d levels and disease activity in ankylosi...
7614647 - Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery.
3418087 - The clinical significance of serum c reactive protein levels in crohn's disease. result...
18187137 - Cystatin c--a marker of peripheral atherosclerotic disease?
18360867 - Does gadolinium-based angiography protect against contrast-induced nephropathy?: a syst...
15534737 - Coagulopathy and hyperfibrinolysis in ruptured abdominal aortic aneurysm repair.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The British journal of dermatology     Volume:  154     ISSN:  0007-0963     ISO Abbreviation:  Br. J. Dermatol.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-15     Completed Date:  2006-08-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0004041     Medline TA:  Br J Dermatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  726-9     Citation Subset:  IM    
Dermatology Department, Waterford Regional Hospital, Waterford, Ireland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dermatologic Agents / therapeutic use*
Health Status Indicators
Hidradenitis Suppurativa / drug therapy*
Immunoglobulin G / therapeutic use*
Quality of Life
Receptors, Tumor Necrosis Factor / therapeutic use*
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Reg. No./Substance:
0/Dermatologic Agents; 0/Immunoglobulin G; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Life quality assessment among patients with atopic eczema.
Next Document:  Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before a...